Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy, National Research and Innovation Agency (BRIN), Jakarta, Indonesia
Ms. Isti Daruwati
Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy, National Research and Innovation Agency (BRIN), Jakarta, Indonesia
The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted the quest for prophylactic agents that can be used to combat COVID-19. This study presents the feasibility of chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 as a strong candidate to neutralize the virus for application in passive immunization. For the purpose of preclinical studies, we radiolabeled IgY anti-RBD spike SARS-CoV-2 with radionuclide iodine-131. This allowed us to evaluate several biological characteristics of IgY in vitro, in vivo, and ex vivo. The preclinical data suggest that IgY anti-RBD spike SARS-CoV-2 could specifically bind to the SARS-CoV-2 antigens; however, little uptake was observed in normal cells (MRC-5) (<2%). Furthermore, the ex vivo biodistribution study revealed that IgY predominantly accumulated in the trachea of normal mice compared to other organs. We also found that IgY possessed a good safety profile when used as an intranasal agent. Taken together, we propose that IgY anti-RBD spike SARS-CoV-2 has the potential for application in passive immunization against COVID-19.
Natural compounds provide precursors with various pharmacological activities and play an important role in discovering new chemical entities, including radiopharmaceuticals. In the development of new radiopharmaceuticals, iodine radioisotopes are widely used and interact with complex compounds including natural products. However, the development of radiopharmaceuticals from natural compounds with iodine radioisotopes has not been widely explored. This review summarizes the development of radiopharmaceuticals from natural compounds using iodine radioisotopes in the last 10 years, as well as discusses the challenges and strategies to improve future discovery of radiopharmaceuticals from natural resources. Literature research was conducted via PubMed, from which 32 research articles related to the development of natural compounds labeled with iodine radioisotopes were reported. From the literature, the challenges in developing radiopharmaceuticals from natural compounds were the purity and biodistribution. Despite the challenges, the development of radiopharmaceuticals from natural compounds is a golden opportunity for nuclear medicine advancement.
28 February 2019 in Jurnal Sains dan Teknologi Nuklir Indonesia
Berkembangnya ilmu pengetahuan dan informasi di bidang kesehatan membuat masyarakat meyakini bahwa mengkonsumsi makanan yang kaya antioksidan penting untuk mencegah berbagai penyakit degeneratif seperti penyakit jantung dan kanker. Kuersetin merupakan senyawa flavonoid yang banyak ditemukan pada buah dan sayur yang memiliki aktivitas antioksidan yang sangat kuat. Banyak penelitian yang telah membuktikan efektivitas kuersetin sebagai senyawa antikanker secara in-vitro, namun data pengujiannya secara in-vivo masih terbatas. 99mTc-kuersetin diharapkan dapat dijadikan radiotracer untuk mengetahui efektivitas senyawa kuersetin sebagai senyawa antikanker pada pengujian in-vivo menggunakan hewan percobaan. Namun sebelum dilakukan pengujian in-vivo untuk menjamin aplikasinya perlu dilakukan pengujian karakteristik fisiko-kimia sediaan 99mTc-kuersetin. Oleh karena itu tujuan dari penelitian ini adalah untuk mengetahui karakteristik fisiko-kimia dari senyawa 99mTc-kuersetin. Hasil penelitian karakteristik fisiko-kimia 99mTc-kuersetin menunjukkan bahwa kemurnian radiokimia sediaan 99mTc-kuersetin adalah 98,94 ± 0,30%. Sediaan 99mTc-Kuersetin ini bermuatan netral, memiliki nilai lipofilisitas dengan log (P) = 0,62 ± 0,05 dan dapat berikatan kuat dengan plasma darah dengan persentase sebesar 95,06 ± 1,34%.Berdasarkan nilai lipofilisitas sebesar 0,62 ± 0,05 diharapkan senyawa ini akan mudah terdistribusi kedalam jaringan organ sehingga diharapkan akan efektif sebagai senyawa bertanda penyidik kanker.
The high rate of incidence and mortality caused by breast cancer encourage urgent research to immediately develop new diagnostic and therapeutic agents for breast cancer. Alpha mangostin (AM) is a natural compound reported to have anti-breast cancer properties. Its electron-donating groups structure allows it to be labeled with an iodine-131 radioisotope to develop a candidate of a diagnostic and therapeutic agent for breast cancer. This study aims to prepare the [131I]Iodine-α-mangostin ([131I]I-AM) and evaluate its stability, lipophilicity, and cellular uptake in breast cancer cell lines. The [131I]I-AM was prepared by direct radiosynthesis with Chloramine-T method in two conditions (A: AM dissolved in NaOH, B: AM dissolved in ethanol). Reaction time, pH, and mass of the oxidizing agent were optimized as crucial parameters that affected the radiosynthesis reaction. Further analysis was conducted using the radiosynthesis conditions with the highest radiochemical purity (RCP). Stability tests were carried out at three storage conditions, including −20, 2, and 25 °C. A cellular uptake study was performed in T47D (breast cancer cell line) and Vero cells (noncancerous cell line) at various incubation times. The results show that the RCP values of [131I]I-AM under conditions A and B were 90.63 ± 0.44 and 95.17 ± 0.80% (n = 3), respectively. In the stability test, [131I]I-AM has an RCP above 90% after three days of storage at −20 °C. A significant difference was obtained between [131I]I-AM uptake in T47D and Vero cells. Based on these results, [131I]I-AM has been prepared with high RCP, stable at −20 °C, and specifically uptaken by breast cancer cell lines. Biodistribution evaluations in animals are recommended as further research in developing [131I]I-AM as a diagnostic and therapeutic agent for breast cancer.
Estradiol is a steroid hormone that works as an agonist estrogen receptor (ER). This compound is widely used as a ligand and bind specifically to the ERα. Radioligand binding assay is an in vitro method for drug development from natural products by synthesizing estradiol through radiolabeling using the radioiodination method. Synthesis of 131I-estradiol was perfomed by direct method using chloramine T as an oxidizer and by indirect labeling using 131I-histamine. The purity of chemical was determined by thin-layer chromatography and paper electrophoresis, as well as its stability for 30 days of storage in refrigerator, freezer and room temperature. The cellular uptake test of the radioligands from both methods was carried out with MCF7 and T-47D cell lines at 60 min. The results exhibited that 131I-estradiol was succesfully obtained with radiochemical purity greater than 95% and more stable in the refrigerator until 21 days than freezer and room temperature. 131I-estradiol and 131I-his-estradiol were internalized higher in T-47D cells than MCF7 cells (44.34 ± 5.93% vs. 17.27 ± 1.71% and 45.34 ± 6.42% vs. 4.92 ± 1.59%, respectively). Furthermore, the radioligands can be used to binding assay in determining the agonist or antagonist to ER of new drugs development.
1 May 2024 in Journal of Pharmacy & Pharmacognosy Research
J. Pharm. Pharmacogn. Res., vol. 12, no. 3, pp. 423-438, May-Jun 2024. DOI: https://doi.org/10.56499/jppres23.1827_12.3.423 Original Article Synthesis and computational study of metal complex of α-mangostin as an anticancer candidate [Síntesis y estudio computacional de un complejo metálico de α-mangostin como un candidato anticancerígeno] Richa Mardianingrum1, Srie Rezeki Nur Endah1, Isti Daruwati2,3, Muchtaridi Muchtaridi3,4, Ruswanto Ruswanto5* Synthesis and computational study of metal complex of α-mangostin as an anticancer candidate